» Articles » PMID: 31493960

Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates

Overview
Journal Eur Urol
Specialty Urology
Date 2019 Sep 9
PMID 31493960
Citations 472
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility.

Objective: To assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-date incidence and mortality data.

Evidence Acquisition: We present estimated age-standardized prostate cancer incidence and mortality rates by country and world regions for 2018 based on the GLOBOCAN database. We also examined rates and temporal trends for incidence (44 countries) and mortality (76 countries) based on data series from population-based registries.

Evidence Synthesis: The highest estimated incidence rates were found in Australia/New Zealand, Northern America, Western and Northern Europe, and the Caribbean, and the lowest rates were found in South-Central Asia, Northern Africa, and South-Eastern and Eastern Asia. The highest estimated mortality rates were found in the Caribbean (Barbados, Trinidad and Tobago, and Cuba), sub-Saharan Africa (South Africa), parts of former Soviet Union (Lithuania, Estonia, and Latvia), whereas the lowest rates were found in Asia (Thailand and Turkmenistan). Prostate cancer incidence rates during the most recent 5 yr declined (five countries) or stabilized (35 countries), after increasing for many years; in contrast, rates continued to increase for four countries in Eastern Europe and Asia. During the most recent 5 data years, mortality rates among the 76 countries examined increased (three countries), remained stable (59 countries), or decreased (14 countries).

Conclusions: As evident from available data, prostate cancer incidence and mortality rates have been on the decline or have stabilized recently in many countries, with decreases more pronounced in high-income countries. These trends may reflect a decline in prostate-specific antigen testing (incidence) and improvements in treatment (mortality).

Patient Summary: We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates in most countries stabilized or decreased.

Citing Articles

Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15.

Han C, Yang B, Deng Y, Hu P, Hu B, Liu X Chin Med. 2025; 20(1):35.

PMID: 40087774 DOI: 10.1186/s13020-025-01086-1.


Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives.

Li X, Yang F, Wang M, Huang X, Zeng X, Zhou L Front Pharmacol. 2025; 16:1478331.

PMID: 40078274 PMC: 11897510. DOI: 10.3389/fphar.2025.1478331.


ABO blood group system correlates with preoperative serum PSA level in patients with prostate cancer.

Wang F, Zhang Y, Xing N, Li J Sci Rep. 2025; 15(1):8586.

PMID: 40075227 PMC: 11904218. DOI: 10.1038/s41598-025-93728-5.


A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer.

Prive B, Govers T, Israel B, Janssen M, Timmermans B, Peters S Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40072531 DOI: 10.1007/s00259-025-07190-6.


A Bidirectional Mendelian Randomization Study on the Causal Relationship Between Epstein-Barr Virus Antibodies and Prostate Cancer Risk.

Ding X, Ren S, Wen H, Zhang Z, Ye J, Pan W Cancer Control. 2025; 32:10732748251320842.

PMID: 40026212 PMC: 11873887. DOI: 10.1177/10732748251320842.